ATE479437T1 - Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung - Google Patents

Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung

Info

Publication number
ATE479437T1
ATE479437T1 AT04803089T AT04803089T ATE479437T1 AT E479437 T1 ATE479437 T1 AT E479437T1 AT 04803089 T AT04803089 T AT 04803089T AT 04803089 T AT04803089 T AT 04803089T AT E479437 T1 ATE479437 T1 AT E479437T1
Authority
AT
Austria
Prior art keywords
düpyrimidine
benzoä4
therapeutic use
therapeutic
Prior art date
Application number
AT04803089T
Other languages
German (de)
English (en)
Inventor
Leena Hirvelae
Nina Johansson
Pasi Koskimies
Olli Taneli Pentikaeinen
Tommi Nyroenen
Tiina Annamaria Salminen
Mark Stuart Johnson
Pekka Lehtovuori
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Application granted granted Critical
Publication of ATE479437T1 publication Critical patent/ATE479437T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Joining Of Glass To Other Materials (AREA)
AT04803089T 2003-06-10 2004-06-09 Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung ATE479437T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47704703P 2003-06-10 2003-06-10
PCT/EP2004/006230 WO2005032527A2 (en) 2003-06-10 2004-06-09 Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy

Publications (1)

Publication Number Publication Date
ATE479437T1 true ATE479437T1 (de) 2010-09-15

Family

ID=34421462

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04803089T ATE479437T1 (de) 2003-06-10 2004-06-09 Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung

Country Status (24)

Country Link
US (1) US7465739B2 (enExample)
EP (1) EP1635839B1 (enExample)
JP (1) JP4605800B2 (enExample)
KR (1) KR20060054189A (enExample)
CN (1) CN1791412A (enExample)
AR (1) AR044650A1 (enExample)
AT (1) ATE479437T1 (enExample)
AU (1) AU2004277311B8 (enExample)
BR (1) BRPI0411295A (enExample)
CA (1) CA2527617A1 (enExample)
DE (1) DE602004028934D1 (enExample)
DK (1) DK1635839T3 (enExample)
ES (2) ES2352552T3 (enExample)
IL (1) IL172316A0 (enExample)
MX (1) MXPA05012745A (enExample)
NO (1) NO20060123L (enExample)
PL (1) PL1635839T3 (enExample)
PT (1) PT1635839E (enExample)
RU (1) RU2412190C2 (enExample)
SA (1) SA04250159B1 (enExample)
SI (1) SI1635839T1 (enExample)
TW (1) TWI349551B (enExample)
WO (1) WO2005032527A2 (enExample)
ZA (1) ZA200508296B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
WO2005108376A1 (en) * 2004-05-06 2005-11-17 Smithkline Beecham Corporation Calcilytic compounds
WO2006044826A2 (en) * 2004-10-20 2006-04-27 Compass Pharmaceuticals Llc Thiophens and their use as anti-tumor agents
BRPI0419229A (pt) * 2004-12-13 2007-12-18 Solvay Pharm Gmbh derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
FR2904000A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee
FR2904318B1 (fr) * 2006-07-27 2011-02-25 Scras Derives de pyrimidinone et leur utilisation comme medicament
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
DE102007015169A1 (de) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
WO2009001214A2 (en) * 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
DE102007040243A1 (de) * 2007-08-25 2009-02-26 Universität des Saarlandes 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
EP2381775A4 (en) * 2008-12-23 2012-08-15 Harvard College INHIBITORS OF NECROPTOSIS OF SMALL MOLECULAR SIZE
EP2609089A1 (en) 2010-08-27 2013-07-03 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2012119605A1 (en) * 2011-03-10 2012-09-13 Akar Yahya Ahmed Abdellhafeez Salem New disperse dye with potent anticancer activity
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
AR096728A1 (es) 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados de estratrieno-tiazol terapéuticamente activos
AR096729A1 (es) 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados terapéuticamente activos de estratien-tiazol
JP6456373B2 (ja) 2013-06-25 2019-01-23 フォレンド ファーマ リミテッド １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体
EP3089969A2 (en) 2014-01-03 2016-11-09 Elexopharm GmbH Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
GB201419102D0 (en) * 2014-10-27 2014-12-10 Imp Innovations Ltd Novel compounds
WO2016102775A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd PRODRUGS OF 17β-HSD1 -INHIBITORS
JP6523461B2 (ja) 2014-12-23 2019-06-05 フォレンド ファーマ リミテッド １７β−ＨＳＤ１−阻害剤のプロドラッグ
CA3003930A1 (en) * 2015-11-04 2017-05-11 Simon Fraser University Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor
DK3634975T3 (da) 2017-06-08 2024-05-27 Organon R&D Finland Ltd 17-oximer af 15.beta.-[3-propanamido]-substituerede estra-1,3,5(10)-trien-17-oner til anvendelse i inhibition af 17.beta.-hydroxysteroid-dehydrogenaser
CN109503572B (zh) * 2017-09-15 2021-10-08 上海交通大学 一种合成吲哚喹啉类化合物的方法
CA3122049C (en) 2018-12-05 2023-10-17 Forendo Pharma Ltd Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1
AU2023260728A1 (en) * 2022-04-28 2024-10-10 Enanta Pharmaceuticals, Inc. Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors
US20250154163A1 (en) * 2023-10-26 2025-05-15 Enanta Pharmaceuticals, Inc. Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4742271B1 (enExample) * 1968-06-20 1972-10-25
US3775027A (en) 1971-10-01 1973-11-27 Gray Manuf Co Inc Two-speed pump
JPS62132884A (ja) 1985-12-05 1987-06-16 Mitsubishi Chem Ind Ltd ２−ベンジルチエノ〔２，３−ｄ〕ピリミジン−４（３Ｈ）−オン誘導体
WO1989008113A1 (en) 1988-03-02 1989-09-08 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL APPLICATION THEREOF
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
JP3783810B2 (ja) 1997-01-14 2006-06-07 第一製薬株式会社 新規ベンゾフラノン誘導体及びその製造方法
JPH10273467A (ja) 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
AU9001698A (en) 1997-09-11 1999-03-29 Snow Brand Milk Products Co., Ltd. Remedies for hormone-dependent diseases
TR200002784T2 (tr) 1998-03-11 2000-12-21 Endorecherche, Inc Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
US6291505B1 (en) 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
GB9929302D0 (en) 1999-12-11 2000-02-02 Univ Cardiff Benzyl tetralins compositions and uses thereof
AU2001296961A1 (en) 2000-09-29 2002-04-08 Bayer Pharmaceuticals Corporation 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
ES2276950T3 (es) 2001-09-06 2007-07-01 Schering Corporation Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
US6750248B2 (en) 2001-11-09 2004-06-15 National University Of Singapore Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof

Also Published As

Publication number Publication date
US7465739B2 (en) 2008-12-16
RU2006100033A (ru) 2007-07-20
MXPA05012745A (es) 2006-05-17
TW200509937A (en) 2005-03-16
AU2004277311B8 (en) 2010-05-27
WO2005032527A3 (en) 2005-08-04
AU2004277311A1 (en) 2005-04-14
TWI349551B (en) 2011-10-01
WO2005032527B1 (en) 2005-09-22
ZA200508296B (en) 2007-01-31
AR044650A1 (es) 2005-09-21
EP1635839B1 (en) 2010-09-01
AU2004277311B2 (en) 2010-04-29
KR20060054189A (ko) 2006-05-22
PT1635839E (pt) 2010-10-12
SA04250159B1 (ar) 2008-06-21
CN1791412A (zh) 2006-06-21
BRPI0411295A (pt) 2006-08-01
NO20060123L (no) 2006-03-09
EP1635839A2 (en) 2006-03-22
ES2352552T3 (es) 2011-02-21
DK1635839T3 (da) 2011-01-03
PL1635839T3 (pl) 2011-02-28
RU2412190C2 (ru) 2011-02-20
DE602004028934D1 (de) 2010-10-14
IL172316A0 (en) 2011-08-01
JP4605800B2 (ja) 2011-01-05
US20050038053A1 (en) 2005-02-17
CA2527617A1 (en) 2005-04-14
JP2006527226A (ja) 2006-11-30
SI1635839T1 (sl) 2010-12-31
ES2352554T3 (es) 2011-02-21
WO2005032527A2 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
ATE479437T1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
DE60314600D1 (de) O-cyclopropyl-carboxanilide und ihre verwendung als fungizide
DE50207849D1 (de) Substituierte 2-oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung
EE05505B1 (et) Personaalne teraapiasektsioon
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
NL1025404A1 (nl) Pyrazolo-triazine verbindingen en gebruik daarvan.
ATE409700T1 (de) Cannabinoid rezeptor-liganden und ihre verwendung
EP1746902A4 (en) MULTI-LECTIN AFFINITY CHROMATOGRAPHY AND USES THEREOF
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
DE602004010426D1 (de) Mikrobizide zusammensetzungen und ihre verwendung
ATE419366T1 (de) Tyra-gene und ihre verwendung
ATE384054T1 (de) Substituierte benzoxazinones und ihre verwendung
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
ATE362469T1 (de) 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
DE60230162D1 (de) Polymerisate und ihre verwendung
ATE396994T1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
DK1597171T3 (da) Terapeutisk mikroskum
DE60311598D1 (de) Naphthyridin-derivate und ihre verwendung als fungizide
NO20050689L (no) Terapeutisk anvendelse
DE60324586D1 (de) Substituierte pyridyloxyalkylamide und ihre verwendung als fungizide
DE602005020457D1 (de) Master-slave-flip-flop, trigger-flip-flop und zähler
DE50313185D1 (de) 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1635839

Country of ref document: EP